Isis, Genzyme Submit Antisense Cholesterol Drug for European Approval
July 28, 2011
* Type size: - +
* ""
* Printer-friendly version
* RSS Feed
Specifically, the companies are seeking clearance to commercialize the 200 mg weekly dose of the drug for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
Once again correct ACE.....
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
-0.001(9.09%) |
Mkt cap ! $10.87M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.0¢ | $7.664K | 746.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 4019355 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 2773627 | 9 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| PER (ASX) Chart |